Dyslipidemia

Post hoc analysis of REAL-CAD shows the cholesterol metric does not serve to inform statin treatment control of coronary artery disease.

New data shows that high BMI individuals who were in the lowest polygenic score quintile had a 5-fold greater risk of diabetes than those with low BMI and a high polygenic score.

According to late breaking data, younger women exhibit a decreased risk for heart attack mortality due to estrogen’s protective effect

What ESC has learned about the benefits and difficulties of online-only forums.

Evolocumab and alirocumab produced LDL-C reduction in patients regardless of underlying mutations, investigators reported.

Myocardial infarction patients were provided ECG readings as reliable as those provided by standard devices.

Studies have shown that heat-related cardiovascular events have increased over recent years.

New cohort data shows that at least 40% of COVID-19 positive patients had CV risk factors, such as diabetes and hypertension.

Dapagliflozin and empagliflozin are shown to minimize CV events in patients with heart failure and a reduced ejection fraction.

New findings suggest the "obesity paradox" may be explained by rates of exercise among women.

Accurately assessing lifetime risk in patients with developing atherosclerosis may help reduce CV disease risk earlier in life.

The CLEAR Harmony open-label extension study reports on the long-term effects of BA treatment for hypercholesterolemia.

The new findings break ground on placebo-controlled assessment of the PCSK9 inhibitor for the pediatric population.

Up to 91% patients who received maximum dosage of the drug achieved a triglyceride level of <150 mg/dL, according to new data presented at ESC 2020.

Daniel Gaudet, MD, PhD, discusses what's next in clinical pursuits of the greatly underdiagnosed hereditary cardiovascular disease.

Investigators simulated baseline CV risk and predicted potential risk reduction among a cohort of evolocumab users across Europe.

A podcast interview with the president of American Society of Preventive Cardiology, on the eve of the ESC 2020 Congress.

PCSK9 inhibitor therapy within 24 hours after PCI was shown to bring LDL-C levels down closer to guideline-recommended goals.

An analysis of data from a Society of Vascular Surgeons registry is shedding light on the use of DAPT in patients following peripheral vascular interventions.

Results of the study suggest that patients with premature and extremely premature ASCVD are at risk for a higher accrued lifetime morbidity.

Full results of the phase 3 ELIPSE HoFH offer the greatest overview yet of the effects of evinacumab in patients with homozygous familial hypercholesterolemia.

A meta-analysis of 4 randomized trials is shedding light on the efficacy and safety of direct oral anticoagulant use for reducing recurrent VTE in patients with cancer.

Treatment with the PCSK9 Inhibitor did not increase risk of safety events, including new-onset diabetes.

A prespecified analysis of FOURIER is detailing the impact of evolocumab on CV events and LDL-C in patients with metabolic syndrome.

New data shows an adherence to troponin testing could complement optimized care.